一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Amivantamab；Lazertinib；Carboplatin；Pemetrexed，当前状态为招募中。登记地点显示中国北京、Cheng Du Shi、成都、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Amivantamab；Lazertinib；Carboplatin；Pemetrexed · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital of Peking University · 北京
- Sichuan Cancer Hospital · Cheng Du Shi
- West China Hospital Sichuan University · 成都
- Guangdong Provincial People's Hospital · 广州
- Shandong Cancer Hospital · 济南
- Shanghai Pulmonary Hospital · 上海
- Tianjin Chest Hospital · 天津
公开的入选条件
- * Participant must have histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC) with completely resectable Stage II-IIIB N2 disease
- * Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a multidisciplinary team evaluation
- * Participant must consent to a screening biopsy, if clinically feasible, if no adequate tumor tissue is available for a baseline sample
- * Participant may have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s). Prior or concurrent se
- * Have an eastern cooperative oncology group (ECOG) performance status of 0 or 1
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07586202；登记信息更新于 2026-09-25。